Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland
Virax Biolabs (NASDAQ: VRAX) has signed a distribution agreement with Europa Biosite to commercialize its ImmuneSelect Research Use portfolio in the United Kingdom and Ireland through Cambridge Bioscience subsidiary. The partnership aims to expand Virax's commercial presence in these markets, making ImmuneSelect's immune profiling solutions accessible to researchers and pharmaceutical companies studying T cell response and immune status. Europa Biosite will provide local technical support and leverage its commercial infrastructure for product delivery.
Virax Biolabs (NASDAQ: VRAX) ha firmato un accordo di distribuzione con Europa Biosite per commercializzare il suo portafoglio ImmuneSelect Research Use nel Regno Unito e in Irlanda attraverso la filiale di Cambridge Bioscience. La partnership mira ad espandere la presenza commerciale di Virax in questi mercati, rendendo le soluzioni di profilazione immunitaria di ImmuneSelect accessibili ai ricercatori e alle aziende farmaceutiche che studiano la risposta delle cellule T e lo stato immunitario. Europa Biosite fornirà supporto tecnico locale e sfrutterà la propria infrastruttura commerciale per la consegna dei prodotti.
Virax Biolabs (NASDAQ: VRAX) ha firmado un acuerdo de distribución con Europa Biosite para comercializar su cartera de uso de investigación ImmuneSelect en el Reino Unido e Irlanda a través de la filial de Cambridge Bioscience. La colaboración tiene como objetivo expandir la presencia comercial de Virax en estos mercados, haciendo que las soluciones de perfilado inmunológico de ImmuneSelect sean accesibles para investigadores y empresas farmacéuticas que estudian la respuesta de las células T y el estado inmunológico. Europa Biosite proporcionará soporte técnico local y aprovechará su infraestructura comercial para la entrega de productos.
Virax Biolabs (NASDAQ: VRAX)는 Europa Biosite와의 배급 계약을 체결하여, 영국과 아일랜드에서 Cambridge Bioscience 자회사를 통해 ImmuneSelect 연구용 포트폴리오를 상용화합니다. 이 파트너십은 Virax의 상업적 존재감을 이 시장에서 확대하여, T 세포 반응 및 면역 상태를 연구하는 연구자와 제약 회사들이 ImmuneSelect의 면역 프로파일링 솔루션을 이용할 수 있도록 하는 것을 목표로 합니다. Europa Biosite는 현지 기술 지원을 제공하고 제품 배송을 위한 상업적 인프라를 활용할 것입니다.
Virax Biolabs (NASDAQ: VRAX) a signé un accord de distribution avec Europa Biosite pour commercialiser son portefeuille ImmuneSelect pour la recherche au Royaume-Uni et en Irlande via la filiale Cambridge Bioscience. Ce partenariat vise à étendre la présence commerciale de Virax sur ces marchés, rendant les solutions de profilage immunitaire d'ImmuneSelect accessibles aux chercheurs et aux entreprises pharmaceutiques étudiant la réponse des cellules T et l'état immunitaire. Europa Biosite fournira un support technique local et tirera parti de son infrastructure commerciale pour la livraison des produits.
Virax Biolabs (NASDAQ: VRAX) hat einen Vertriebsvertrag mit Europa Biosite unterzeichnet, um sein ImmuneSelect-Forschungsportfolio im Vereinigten Königreich und in Irland über die Tochtergesellschaft Cambridge Bioscience zu vermarkten. Die Partnerschaft zielt darauf ab, die kommerzielle Präsenz von Virax in diesen Märkten zu erweitern und damit die Immunprofiling-Lösungen von ImmuneSelect für Forscher und Pharmaunternehmen, die die T-Zell-Antwort und den Immunstatus untersuchen, zugänglich zu machen. Europa Biosite wird lokale technische Unterstützung bieten und seine kommerzielle Infrastruktur für die Produktlieferung nutzen.
- Strategic distribution agreement expanding market presence in UK and Ireland
- Partnership with established distributor providing local technical support
- Access to Europa Biosite's existing commercial infrastructure
- None.
Insights
The distribution agreement with Europa Biosite represents a modest strategic expansion but offers immediate financial impact. While it opens access to the UK and Ireland markets for Virax's ImmuneSelect portfolio, several factors temper the near-term significance: research-use-only (RUO) products typically have smaller market sizes compared to diagnostic products and the agreement is restricted to two countries.
The partnership leverages Europa Biosite's established distribution network and technical support infrastructure, potentially reducing market entry costs. However, without disclosed financial terms, revenue projections, or market size estimates, the agreement's material impact remains uncertain. The focus on T cell response research aligns with growing immunology research trends but operates in a competitive space with established players.
"ImmuneSelect is an important suite of profiling solutions for assessing adaptive immunity and we are pleased to partner with Europa Biosite, a leader in life science distribution across
"We are happy to partner with innovative companies like Virax Biolabs," commented Martijn Blommaart, Director of Supplier Development at Europa Biosite. "We look forward to leveraging our commercial infrastructure to quickly deliver and provide local technical support to ensure that ImmuneSelect is available in the
About ImmuneSelect
ImmuneSelect is the Company's portfolio of research products dedicated to investigating adaptive immunity. Products within the ImmuneSelect brand are for research and investigational use only and are not intended to be used as a diagnostics tool. The ImmuneSelect portfolio includes peptide pools covering epitopes from pathogens, optimized for the stimulation of T cells. The initial offerings include pools for SARS-CoV-2, SARS-CoV-2 MHC-1 ("CD8"), Lyme Disease, Cytomegalovirus ("CMV"), Respiratory Syncytial Virus ("RSV") and Epstein-Barr Virus ("EBV"), which continue to be regularly expanded. ImmuneSelect's Recombinant Antibodies target cytokines and biomarkers, and they are available in different versions unconjugated to be tested on a range of applications including Flow Cytometry, ELISA and ELISpot/Fluorospot. ImmuneSelect is affordable, easy to use, and is compatible with most standard laboratory equipment.
About Europa Biosite
Europa Biosite is a European supplier of life science products and services, composed of six leading distribution companies: Biomol in
For more information, please visit https://www.europabiosite.com/.
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.
For more information, please visit www.viraxbiolabs.com.
Investor Relations Contact:
Russo Partners, LLC
Nic Johnson
12 West 27th Street
4th Floor
M: 303-482-6405
nic.johnson@russopartnersllc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-announces-distribution-agreement-with-europa-biosite-to-commercialize-immuneselect-in-the-united-kingdom-and-ireland-302283521.html
SOURCE Virax Biolabs
FAQ
What is the new distribution agreement announced by Virax Biolabs (VRAX) in October 2023?
Which markets will ImmuneSelect be distributed in under the new VRAX agreement?
What product line is Virax Biolabs (VRAX) distributing through Europa Biosite?
